European Journal Of Haematology · 2003 · 29 citations · 25 references
MedicineHematologyPharmacotherapyImmunoregulationImmunotherapyStem Cell TransplantationHematologic ToxicityImmunomodulatory DrugsImmunosuppressionAdverse Treatment EffectsAllogeneic Stem Cell TherapyTumor Necrosis Factor TherapyVascular Endothelial Growth Factor
Except rare instances of allogeneic stem cell transplantation, treatment of idiopathic myelofibrosis (IMF) is only palliative and based on cytostatic treatment (hydroxyurea and anagrelide), androgen therapy, steroids and splenectomy. Thalidomide is an anti-angiogenic and immunomodulatory drug with a wide spectrum of activities, which are not clearly understood. Current data suggest that the action of thalidomide is related to several different mechanisms, including suppression of tumor necrosis factor, effects on basic fibroblast growth factor, vascular endothelial growth factor, interleukins and interferons, downregulation of selected cell surface adhesion molecules, and changes in the lymphocyte subsets. We administered thalidomide to 16 patients with IMF (15 men, one women) who had transfusion-dependent anemia, thrombocytopenia or symptomatic splenomegaly. Median age was 59 yr (range: 52-78). Patients received thalidomide at an escalating dose from 100 to 400 mg/d (median 300 mg). The drug was discontinued in four patients because of progressive disease (two) or polyneuropathy (two). Other adverse effects were obstipation (10), fatigue (eight) and edema (two). Clinical response has now been observed for a median duration of 9 months (range: 3-20). Fifteen patients are evaluable. Anemia improved in six of 10 patients who were anemic. Platelet counts improved in five of seven patients with thrombocytopenia. Splenomegaly regressed in three of 13 patients. Lactate dehydrogenase (LDH) decreased in seven of 12 patients, but increased in four patients. LDH levels were not correlated with clinical response. In summary, thalidomide appears useful in the treatment of IMF.
25
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text
Medicine, Hematology, Oncology +14
Thalidomide is an inhibitor of angiogenesis.
Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations
Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 905 citations
Medicine, Immunology, Oncology +12
Pharmacokinetic Parameters in CNS Gd-DTPA Enhanced MR Imaging
Gunnar Brix, Wolfhard Semmler, Rüdiger E. Port et al. · Journal of Computer Assisted Tomography · 1991 · 665 citations
Patrick Haslett, Laura G. Corral, Matthew L. Albert et al. · The Journal of Experimental Medicine · 1998 · 573 citations · Full text